Hailai Xinchuang Closes $77 Million Round for Tumor Treating Fields Device
July 16, 2021 at 06:05 AM EDT
Jiangsu Hailai Xinchuang Medical Technology closed a $77 million Series C funding to advance its Tumor Treating Fields (TTF) electrical pulse technology for cancer. TTF is designed to interfere with cancer cell division. Hailai has started a multi-center China clinical trial of EFE-G100 in glioblastoma patients, with positive initial results. The company will report an interim analysis from the data in 2022. The latest funding was led by YF Capital, with participation from Temasek, Lilly Asia Ventures, 3H Health Investment, CITIC and Qiming. More details.... Share this with colleagues: // //
